目的 探討托法替布所致不良反應(yīng)（ADR）的發(fā)生規(guī)律和特點(diǎn)，為臨床安全合理用藥提供參考。方法 檢索中國(guó)知網(wǎng)、萬(wàn)方、維普、PubMed、Embase以及Web of Science數(shù)據(jù)庫(kù)中有關(guān)托法替布ADR的個(gè)案報(bào)道，并進(jìn)行數(shù)據(jù)提取與分析。結(jié)果 收集托法替布ADR個(gè)案報(bào)道13例，其中女性8例，男性5例，年齡多集中在50～59歲。托法替布相關(guān)ADR平均發(fā)生在用藥后1年余，主要以皮膚及其附件損害較多，在停藥/減量或?qū)ΠY治療后好轉(zhuǎn)。結(jié)論 托法替布相關(guān)ADR多在長(zhǎng)期用藥后發(fā)生，尤其應(yīng)重視皮膚ADR和感染的防治。臨床用藥時(shí)需要加強(qiáng)用藥監(jiān)測(cè)，及時(shí)識(shí)別，準(zhǔn)確處置，確保用藥安全。

Objective To investigate the occurrence and characteristics of adverse drug reaction (ADR) caused by tofacitinib and to provide reference for clinical safe and rational drug use. Methods Literature related to ADR case reports of tofacitinib were retrieved from CNKI, Wanfang, VIP, PubMed, Embase, and Web of Science databases, and the data were extracted and analyzed. Results A total of 13 ADR cases of tofacitinib were reported, including 8 females and 5 males, mainly aged between 50 and 59 years old. Tofacitinib-related ADR occurred more than 1 year after medication on average. Skin and accessory damage was the most common primary disease. The cases were improved after drug withdrawal/reduction or symptomatic treatment. Conclusion Tofacitinib-related ADRs usually occurred after long-term administration and attention should be paid to the prevention and treatment of skin ADR and infection. It is necessary to strengthen drug monitoring, timely identification and accurate disposal to ensure drug safety.

R979.5